24 May 2013
Keywords: promising, pkc, data, agi, ibs-d, drug, dublin
Article | 25 February 2008
Dublin, Ireland-based AGI Therapeutics has reported encouraging findings on the pharmacokinetic profile of its drug candidate Rezular
(AGI-003), which is ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
10 March 2008
24 September 2007
23 May 2013
© 2013 thepharmaletter.com